ACT: Qualigen obtains exclusive license to novel cancer drug technology from Advanced Cancer Therapeutics

(marketscreener.com) CARLSBAD, Calif., Dec. 18, 2018 /PRNewswire/ -- Qualigen, Inc., and Advanced Cancer Therapeutics, LLC (ACT) today announced that Qualigen has licensed certain ACT patents, intellectual property and know-how associated with the antiproliferative activity of G-rich oligonucleotides ACT-GRO-777 (also known as AS1411) and methods of using these...http://www.marketscreener.com/news/Qualigen-obtains-exclusive-license-to-novel-cancer-drug-technology-from-Advanced-Cancer-Therapeutics--27771280/?utm_medium=RSS&utm_content=20181218